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number of AB’s used. The mean (median) cost for parenteral AB-
therapy was 624.2 (275.3) Euro versus 504.4 (169.1) Euro for
SDT (p < 0.001 Anova). CONCLUSIONS: MBDS through ICD-
9-CM yields valuable information on “real life practice”. The
antibiotic-related cost in SDT is signiﬁcantly lower than full par-
enteral treatment; LOS corrected for age, gender, reason for
admission and departure was unaffected.
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OBJECTIVES: Fatigue is a common, distressing symptom in
HIV+ patients. This analysis evaluates whether substitution to
LPV/r, a generally well tolerated and efﬁcacious PI, affects fatigue
in HIV+ patients experiencing Grade 2 side effects (SE) attrib-
uted to their PI/NNRTI. METHODS: In the open-label PLATO
trial, patients experiencing Grade 2 PI/NNRTI-associated SE
were randomized (4:1) to immediate substitution (IS) of their
PI/NNRTI with LPV/r at baseline or deferred substitution (DS)
at Week 4 (Wk4). The MOS-HIV and ACTG Symptoms Distress
Module, with 2 additional items for nephrolithiasis (ASDM),
were administered at baseline, Wk4 and Wk8. Fatigue was 
measured by MOS-HIV fatigue-domain and ASDM fatigue/
bothersomeness-item. Sleep-disorder was measured by ASDM
sleep-disorder-item. The Center for Epidemiologic Studies-
Depression (CES-D) questionnaire was administered at baseline
and Wk8. RESULTS: Eight hundred twenty-seven patients 
previously on nelﬁnavir (n = 291), indinavir (n = 170), indi-
navir/ritonavir (n = 182), efavirenz (n = 136) or another
PI/NNRTI (n = 48) were analyzed (80% male, mean age 42yrs,
75% with baseline HIV RNA <50 copies/mL). At baseline, mean
MOS-HIV fatigue-domain score was 56.7, with 62.3% rating
fatigue as bothersome. Baseline fatigue scores were correlated 
(p < 0.05) with presence of depression (CES-D >= 16), sleep-
disorder, and years since HIV diagnosis. At Wk4, improved
fatigue scores were seen in IS vs. DS groups (MOS-HIV fatigue-
domain: +8.711 vs. +0.068, p < 0.001; ASDM fatigue/
bothersomeness-item: -0.486 vs. +0.074, p < 0.001), irrespective
of prior PI/NNRTI regimens. At Wk8, fatigue improvement
remained for IS group, while DS group began to improve.
Improved fatigue scores were associated (p < 0.05) with IS,
reduced prevalence of depression, and improved sleep-disorder
scores. Improvement in fatigue and IS were signiﬁcant predictors
of improved MOS-HIV physical health summary score at Wk4
(p < 0.05). CONCLUSIONS: Fatigue scores were improved fol-
lowing substitution with LPV/r, and were associated with
reduced prevalence of depression and improved sleep-disorder
scores. Improvement in fatigue was independent of prior
PI/NNRTI and was a predictor of improved physical health.
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OBJECTIVE: To examine antibiotic prescribing and outcomes
associated with acute sinusitis in managed care. METHODS:
We used the PharMetrics claims database for 8 managed care
organizations. Index claims were based on outpatient visits in
1999–2001 by individuals aged 45–64 with a primary diagnosis
of acute sinusitis who received an antibiotic within 7 days and
were continuously enrolled for 12 months prior to and 45 days
after the index event. Exclusion criteria: antibiotic prescription
or sinusitis diagnosis in prior 45 days, hospitalization in 
prior 30 days, or sinus complications in prior 12 months. Broad
spectrum antibiotics (BSA) were deﬁned as: azithromycin, 
clarithromycin, amoxicillin-clavulanate, second- and third-
generation cephalosporins, quinolones. Sinusitis history was 
categorized: chronic sinusitis (HxChr), acute but not chronic
sinusitis (HxAcu), no history (NoHx). Also, subjects with
asthma, chronic obstructive pulmonary disease (COPD), lower
and upper respiratory tract infection (LRTI, URTI),and rhinitis
in prior year were identiﬁed. Multivariate models adjusted for
age, sex, health plan, use of laboratory/diagnostic testing at
initial evaluation (surrogate for severity and practice variation).
RESULTS: Out of 64,277 cases, 66.1% female, met criteria. Res-
piratory history: 5.4% HxChr, 7.9% HxAcu, 4.5% asthma,
4.4% COPD, 24.6% URTI, 16.3% LRTI, 10.4% rhinitis. BSA
accounted for 45.5% of 1st-line prescriptions. BSA use increased
over 3 years (p < 0.0001): 43.8% (1999), 45.5% (2000), 49.2%
(2001). BSA use was highest for HxChr and asthma at 54.3%.
Overall, 22.4% received a 2nd prescription, highest among
HxChr, 31.7%. Mean charges were $134; highest for HxChr,
$158 and asthma, $152. In multivariate models, respiratory his-
tories were positively associated (p < 0.05) with BSA use, 2nd
prescriptions and charges. CONCLUSION: In treatment of acute
sinusitis in managed care, broad spectrum antibiotics are used
almost 50% of the time as initial therapy and use is rising. Res-
piratory history, especially chronic sinusitis or asthma, is associ-
ated with more BSA use, 2nd prescriptions, and charges.
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OBJECTIVES: This study was conducted to examine the uti-
lization patterns of medical services and prescription drugs in
patients with tinea capitis (TC). METHODS: This retrospective
cohort study identiﬁed TC patients using the MarketScan® data-
base during January 1, 1999–December 31, 2002. Patients were
selected if they had primary or secondary diagnosis of TC (ICD-
9 Code of 110) and had continuous health insurance and pre-
scription drug coverage. The identiﬁed patients were deﬁned as
newly diagnosed patients if they were not diagnosed with TC or
did not use any prescription drugs for TC treatment in the pre-
vious year. The frequency of medical services and the usage pat-
